{"id":"NCT01191086","sponsor":"Upsher-Smith Laboratories","briefTitle":"Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures","officialTitle":"Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2010-08-30","resultsPosted":"2015-02-23","lastUpdate":"2015-02-23"},"enrollment":210,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"USL255","otherNames":["Topiramate extended-release"]}],"arms":[{"label":"Open-label USL255","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.","primaryOutcome":{"measure":"Evaluate the Safety of USL255 Through the Collection of Adverse Events and Clinical Laboratory Evaluations","timeFrame":"Open label treatment of up to 62 weeks","effectByArm":[{"arm":"Open-label USL255","deltaMin":210,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":68,"countries":["United States","Argentina","Australia","Belgium","Canada","Chile","Germany","Greece","India","Israel","New Zealand","Poland","Russia","South Africa","Spain"]},"refs":{"pmids":["27084978"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":210},"commonTop":["Weight decreased","Headache","Somnolence","Dizziness","Aphasia"]}}